{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T08:22:25Z","timestamp":1795162945970,"version":"4.10.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":2618,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.7861\/clinmedicine.17-1-65","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T04:05:17Z","timestamp":1485921917000},"page":"65-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":323,"title":["Psoriatic arthritis: state of the art review"],"prefix":"10.1016","volume":"17","author":[{"given":"Laura C","family":"Coates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.17-1-65_bib1","series-title":"Rheumatology","article-title":"Psoriatic arthritis: clinical features","author":"Helliwell","year":"1998"},{"key":"10.7861\/clinmedicine.17-1-65_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib3","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib4","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2013an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"10.7861\/clinmedicine.17-1-65_bib5","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J Rheumatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.17-1-65_bib7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjd.14604","article-title":"Comparison of screening questionnaires to identify psoriatic arthritis in a primary care population: a cross sectional study","volume":"175","author":"Coates","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3899\/jrheum.140182","article-title":"Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting","volume":"41","author":"Mease","year":"2014","journal-title":"J Rheumatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/art.24608","article-title":"The prevalence of psoriatic arthritis in people with psoriasis","volume":"61","author":"Ibrahim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib13","series-title":"Psoriasis: management of psoriasis. NICE clinical guideline No 153","year":"2012"},{"key":"10.7861\/clinmedicine.17-1-65_bib14","first-page":"38","article-title":"High degree of patient satisfaction and exceptional feedback in a specialist dermatology and rheumatology clinic","volume":"167","author":"Foulkes","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.37939","article-title":"Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2006.056457","article-title":"Predictors for radiological damage in psoriatic arthritis: results from a single centre","volume":"66","author":"Bond","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","article-title":"Predictors of response to intra-articular steroid injection in psoriatic arthritis","volume":"49","author":"Eder","year":"2010","journal-title":"Rheumatology"},{"key":"10.7861\/clinmedicine.17-1-65_bib21","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"key":"10.7861\/clinmedicine.17-1-65_bib22","first-page":"82","volume":"33","author":"Pincus","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate Efficacy in the tight control in psoriatic arthritis study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"issue":"3","key":"10.7861\/clinmedicine.17-1-65_bib24","article-title":"Interventions for psoriatic arthritis","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.7861\/clinmedicine.17-1-65_bib25","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib26","series-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. NICE technology appraisal No 199","year":"2010"},{"key":"10.7861\/clinmedicine.17-1-65_bib27","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib28","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib30","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.17-1-65_bib34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.17-1-65_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.17-1-65_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.17-1-65_bib38","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl S10","key":"10.7861\/clinmedicine.17-1-65_bib39","first-page":"977","article-title":"A Randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients na\u00efve to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.7861\/clinmedicine.17-1-65_bib40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.17-1-65_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","article-title":"The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis","volume":"14","author":"Coates","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.7861\/clinmedicine.17-1-65_bib42","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824023169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824023169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.17-1-65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:36:44Z","timestamp":1761460604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824023169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1470211824023169"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.17-1-65","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic arthritis: state of the art review","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.17-1-65","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2017. All rights reserved.","name":"copyright","label":"Copyright"}]}}